Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.

Importance High levels of ERBB2 (formerly HER2)-specific type 1 T cells in the peripheral blood are associated with favorable clinical outcomes after trastuzumab therapy; however, only a minority of patients develop measurable ERBB2 immunity after treatment. Vaccines designed to increase ERBB2-specific T-helper cells could induce ERBB2 immunity in a majority of patients. Objective To determine the safety and immunogenicity of 3 doses (10, 100, and 500 μg) of a plasmid-based vaccine encoding the ERBB2 intracellular domain (ICD). Design, Setting, and Participants Single-arm phase 1 trial including 66 patients with advanced-stage ERBB2-positive breast cancer treated in an academic medical center between 2001 and 2010 with 10-year postvaccine toxicity assessments. Data analysis was performed over 2 periods: January 2012 to March 2013 and July 2021 to August 2022. Interventions Patients were sequentially enrolled to the 3 dose arms. The vaccine was administered intradermally once a month with soluble granulocyte-macrophage colony-stimulating factor as an adjuvant for 3 immunizations. Toxicity evaluations occurred at set intervals and yearly. Peripheral blood mononuclear cells were collected for evaluation of immunity. Biopsy of vaccine sites at weeks 16 and 36 measured DNA persistence. Main Outcomes and Measures Safety was graded by Common Terminology Criteria for Adverse Events, version 3.0, and ERBB2 ICD immune responses were measured by interferon-γ enzyme-linked immunosorbent spot. Secondary objectives determined if vaccine dose was associated with immunity and evaluated persistence of plasmid DNA at the vaccine site. Results A total of 66 patients (median [range] age, 51 [34-77] years) were enrolled. The majority of vaccine-related toxic effects were grade 1 and 2 and not significantly different between dose arms. Patients in arm 2 (100 μg) and arm 3 (500 μg) had higher magnitude ERBB2 ICD type 1 immune responses at most time points than arm 1 (10 μg) (arm 2 compared with arm 1, coefficient, 181 [95% CI, 60-303]; P = .003; arm 3 compared with arm 1, coefficient, 233 [95% CI, 102-363]; P < .001) after adjusting for baseline factors. ERBB2 ICD immunity at time points after the end of immunizations was significantly lower on average in patients with DNA persistence at week 16 compared with those without persistence. The highest vaccine dose was associated with the greatest incidence of persistent DNA at the injection site. Conclusions and Relevance In this phase 1 nonrandomized clinical trial, immunization with the 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with generation of ERBB2-specific type 1 T cells in most patients with ERBB2-expressing breast cancer, and it is currently being evaluated in randomized phase 2 trials. Trial Registration ClinicalTrials.gov Identifier: NCT00436254.

[1]  M. Delorenzi,et al.  Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. , 2020, Immunity.

[2]  Ligong Chen,et al.  Memory T cells: strategies for optimizing tumor immunotherapy , 2020, Protein & Cell.

[3]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.

[4]  D. Schadendorf,et al.  Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma , 2020, Clinical Cancer Research.

[5]  A. Gallimore,et al.  L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy , 2019, Front. Immunol..

[6]  R. Hershberg,et al.  TLR8 ligation induces apoptosis of monocytic myeloid‐derived suppressor cells , 2018, Journal of leukocyte biology.

[7]  E. Perez,et al.  Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. , 2016, Cancer research.

[8]  S. Halford,et al.  Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes , 2016, Clinical Cancer Research.

[9]  Noah D. Goodman,et al.  Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring. , 2016, JAMA Oncology.

[10]  S. Croft,et al.  Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine , 2015, Gene Therapy.

[11]  J. Waisman,et al.  HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers , 2014, Cancer Immunology, Immunotherapy.

[12]  C. Liu,et al.  Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.

[13]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[14]  D. Turner,et al.  Duration of Antigen Availability Influences the Expansion and Memory Differentiation of T Cells , 2011, The Journal of Immunology.

[15]  J. Waisman,et al.  Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Stevenson,et al.  Prolonged Antigen Expression following DNA Vaccination Impairs Effector CD8+ T Cell Function and Memory Development1 , 2007, The Journal of Immunology.

[17]  Zoe Moodie,et al.  Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. , 2006, Journal of immunological methods.

[18]  Holden T Maecker,et al.  Maximizing the Retention of Antigen Specific Lymphocyte Function after Cryopreservation , 2001 .

[19]  D. Ankerst,et al.  Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT , 2005, BMC Immunology.

[20]  M. Cheever,et al.  Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Dahlin,et al.  Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. , 2003, Molecular cancer therapeutics.

[22]  M. Cheever,et al.  Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.